Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Incyte Corporation.
Burst CME™: Integrating New Therapeutic Options Into Treatment Paradigms for Relapsed/Refractory DLBCL
Release Date: May 14, 2021
Expiration Date: May 14, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Incyte Corporation.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward medical oncologists and hematologists who treat or are interested in the treatment of diffuse large B-cell lymphoma (DLBCL). Other allied health care professionals, including nurse practitioners, physician assistants, and nurses involved in the treatment and management of patients with DLBCL will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the diagnostic and prognostic biomarkers for DLBCL, and their utility in guiding treatment decision-making and patient management
- Integrate new treatment options into evolving treatment algorithms for patients with relapsed/refractory DLBCL, taking into consideration efficacy, safety, and patient-specific factors, to optimize patient outcomes
- Incorporate proactive strategies to mitigate, monitor, and manage adverse events associated with novel therapies used in the treatment of patients with DLBCL
- Consider ongoing clinical trials of investigational agents for DLBCL, and how results from these trials may affect current treatment paradigms
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
Faculty
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Director OSUCCC Lymphoma Research
Department of Internal Medicine
Division of Hematology
The Ohio State University, The James Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.